PO.CL05.07 · 临床研究

三阴性乳腺癌(TNBC)对新辅助化疗-免疫治疗应答的生物学通路

Biological pathways of response to neoadjuvant chemo-immunotherapy in triple-negative breast cancer (TNBC)

海报缩略图:三阴性乳腺癌(TNBC)对新辅助化疗-免疫治疗应答的生物学通路
编号 7768 展板 28 时间 4/22 09:00–12:00 区域 Section 42 主讲 Nickolas Stabellini, MD
分会场 Immune Response to Therapies
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Nickolas Stabellini1, Prerana B. Parthasarathy2, Iluja Gautam3, Patricia A. Rayman2, Monaben Patel2, Paul G. Pavicic Jr2, Adam Moen2, Brian Race2, Eden Mundell2, Amanda Trevino2, Jennifer Powers2, Tyler Joseph Alban2, Jennifer Ko2, Bahar Moftakhar4, Takae Mizukami5, Cynthia Owusu5, Timothy A. Chan6, Alberto J. Montero5, C. Marcela Diaz-Montero2

1Case Western Reserve University School of Medicine, Cleveland, OH,2Cleveland Clinic, Cleveland, OH,3Cleveland Clinic Lerner College of Medicine, Cleveland, OH,4University Hospitals Seidman Cancer Center, Cleveland, OH,5University Hospitals Cleveland Medical Center, Cleveland, OH,6The Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH

摘要 Abstract

中文摘要
背景:KEYNOTE-522确立了新辅助pembrolizumab联合化疗作为早期TNBC的标准治疗,提高了病理完全缓解(pCR)率。然而,多达45%的患者(pts)未能达到pCR,且驱动不同应答的机制尚不清楚。本研究旨在识别在基线(BL)区分pCR与非pCR患者的生物学通路,并表征这些通路在治疗期间(DT)和术后(PS)如何演变。 方法:在BL、DT和PS采集TNBC患者的血液样本。通过密度梯度离心分离外周血单个核细胞(PBMCs)。使用Parse Biosciences平台进行单细胞RNA测序。基因集富集分析使用分子特征数据库(MSigDB)hallmark(50个基因集)和Reactome(1,787个基因集)集合识别富集通路。在每个时间点在pCR与非pCR患者之间以及组内(DT比BL)进行比较。 结果:在18例测序患者中,11例达到pCR。共分析了17种细胞类型的883,183个细胞。在BL,应答者表现出升高的干扰素(IFN)和细胞因子信号(主要来自淋巴细胞),以及经典单核细胞(CM)中趋化因子上调和CD8+T细胞中DAP12表达增加。在治疗期间,应答者表现出髓系驱动的TNFalpha/NFκB炎症应答和CM中GPCR信号上调。相比之下,非应答者在DT时在所有细胞类型中表现出无效的髓系IFN信号和下调的TNFalpha/NFκB活性。 结论:pCR的特征是协调的淋巴细胞和髓系免疫激活。非应答者表现出无效信号和被抑制的炎症通路。这些不同的机制凸显了指导TNBC患者分层和治疗优化的潜在生物标志物。 表1。应答者与非应答者之间差异最显著的通路 通路 MSigDB 基因集 细胞类型 基线(应答者比非应答者) 治疗中(应答者比非应答者) 术后(应答者比非应答者) 抗原提呈与免疫激活 ANTIGEN_PROCESSING_CROSS_PRESENTATION Reactome 经典单核细胞、非经典单核细胞 下调 下调 - BINDING/UPTAKE BY SCAVENGER RECEPTORS Reactome CD8+T细胞 - 上调 上调 REGULATION OF TLR BY ENDOGENOUS LIGAND Reactome 浆细胞 - 下调 上调 T细胞与细胞因子信号 INTERFERON_GAMMA SIGNALING Reactome CD8+T细胞 上调 - 上调 INTERFERON_ALPHA_RESPONSE和INTERFERON_GAMMA_RESPONSE Hallmark CD8+T细胞、CD4+T细胞、B细胞、浆细胞、调节性T细胞、NK细胞 上调 上调 上调 INTERFERON_ALPHA_RESPONSE和INTERFERON_GAMMA_RESPONSE Hallmark 经典单核细胞、非经典单核细胞、树突状细胞 上调 下调 上调 INTERFERON_GAMMA SIGNALING Reactome CD8+T细胞 上调 - 上调 TNFA_SIGNALING_VIA_NFKB Hallmark CD8+T细胞、CD4+T细胞、B细胞、浆细胞、调节性T细胞、NK细胞 上调 上调 上调 CYTOKINE SIGNALING IN IMMUNE SYSTEM Reactome CD8+T细胞、CD4+T细胞 上调 - 上调 INTERFERON_ALPHA_BETA_SIGNALING Reactome 经典单核细胞、CD8+T细胞 上调 - 上调 INTERFERON_SIGNALING Reactome CD8+T细胞、CD4+T细胞 上调 - 上调 INTERFERON_SIGNALING Reactome 经典单核细胞 - 下调 上调 DAP12_INTERACTIONS Reactome CD8+T细胞 上调 - 上调 细胞信号与转运 SIGNALING_BY_GPCR Reactome 经典单核细胞 上调 上调 - GPCR_LIGAND_BINDING Reactome 经典单核细胞 上调 上调 上调 GPCR_LIGAND_BINDING Reactome 浆细胞 - 上调 上调 CHEMOKINE_RECEPTOR_BIND_CHEMOKINES Reactome 经典单核细胞 上调 上调 上调 FORMATION OF BETA-CATENIN TCF COMPLEX Reactome 经典单核细胞 上调 上调 - FORMATION OF BETA-CATENIN TCF COMPLEX Reactome 非经典单核细胞 上调 上调 下调 细胞周期与DNA复制 DNA_METHYLATION Reactome 经典单核细胞 上调 上调 - DNA_METHYLATION Reactome 非经典单核细胞 上调 上调 下调 DNA_METHYLATION Reactome 浆细胞 下调 - 下调 CELL_CYCLE_MITOTIC Reactome 浆细胞 下调 - 下调 CELL_CYCLE_CHECKPOINTS Reactome 浆细胞 下调 - 下调 DNA_REPLICATION Reactome 浆细胞 下调 - 下调 代谢与生物合成 RESPIRATORY_ELECTRON_TRANSPORT Reactome 非经典单核细胞 下调 下调 - HEME_SIGNALING Reactome 未成熟T细胞 上调 上调 - HEPARAN_SULFATE/HEPARIN METABOLISM Reactome 经典单核细胞 下调 - 下调
查看英文原文 English abstract
Background: KEYNOTE-522 established neoadjuvant pembrolizumab plus chemotherapy as standard care for early-stage TNBC, improving pathological complete response (pCR) rates. However, up to 45% of patients (pts) do not achieve pCR, and mechanisms driving differential responses are unclear. This study aimed to identify biological pathways distinguishing pCR from non-pCR pts at baseline (BL) and to characterize how these pathways evolve during treatment (DT) and post-surgery (PS). Methods: Blood samples from TNBC pts were collected at BL, DT, and PS. Peripheral blood mononuclear cells (PBMCs) were isolated by density gradient centrifugation. Single-cell RNA sequencing was performed using the Parse Biosciences platform. Gene Set Enrichment Analysis identified enriched pathways using the Molecular Signatures Database (MSigDB) hallmark (50 gene sets) and Reactome (1,787 gene sets) collections. Comparisons were made between pCR and non-pCR patients at each timepoint and within groups (DT vs. BL). Results: Among 18 sequenced pts, 11 achieved pCR. A total of 883,183 cells across 17 cell types were analyzed. At BL, responders showed elevated interferon (IFN) and cytokine signaling, mainly from lymphocytes, along with chemokine upregulation in classical monocytes (CM) and increased DAP12 expression in CD8+ T cells. During treatment, responders demonstrated a myeloid-driven TNFalpha/NFκB inflammatory response and upregulated GPCR signaling in CM. In contrast, non-responders exhibited ineffective myeloid IFN signaling and downregulated TNFalpha/NFκB activity across all cell types DT. Conclusions: pCR is distinguished by a coordinated lymphocyte and myeloid immune activation. Non-responders exhibit ineffective signaling and suppressed inflammatory pathways. These divergent mechanisms highlight potential biomarkers to guide patient stratification and therapeutic optimization in TNBC. Table 1. Most prominent pathways differing between responders and non-responders Pathway MSigDB Gene set Cell Type Baseline (responders vs non-responders) On treatment (responders vs non-responders) Post-Surgery (responders vs non-responders) Antigen Presentation & Immune Activation ANTIGEN_PROCESSING_CROSS_PRESENTATION Reactome Classical Monocytes, Non-classical Monocytes Downregulated Downregulated - BINDING/UPTAKE BY SCAVENGER RECEPTORS Reactome CD8+ T-cells - Upregulated Upregulated REGULATION OF TLR BY ENDOGENOUS LIGAND Reactome Plasma cells - Downregulated Upregulated T-Cell & Cytokine Signaling INTERFERON_GAMMA SIGNALING Reactome CD8+ T-cells Upregulated - Upregulated INTERFERON_ALPHA_RESPONSE and INTERFERON_GAMMA_RESPONSE Hallmark CD8+ T-cells, CD4+ T-cells, B cells, Plasma cells, regulatory T-cells, NK-cells Upregulated Upregulated Upregulated INTERFERON_ALPHA_RESPONSE and INTERFERON_GAMMA_RESPONSE Hallmark Classical Moncoytes, Non-classical monocytes, Dendritic cells Upregulated Downregulated Upregulated INTERFERON_GAMMA SIGNALING Reactome CD8+ T-cells Upregulated - Upregulated TNFA_SIGNALING_VIA_NFKB Hallmark CD8+ T-cells, CD4+ T-cells, B cells, Plasma cells, regulatory T-cells, NK-cells Upregulated Upregulated Upregulated CYTOKINE SIGNALING IN IMMUNE SYSTEM Reactome CD8+ T-cells, CD4+ T-cells Upregulated - Upregulated INTERFERON_ALPHA_BETA_SIGNALING Reactome Classical Monocytes, CD8+ T-cells Upregulated - Upregulated INTERFERON_SIGNALING Reactome CD8+ T-cells, CD4+ T-cells Upregulated - Upregulated INTERFERON_SIGNALING Reactome Classical Monocytes - Downregulated Upregulated DAP12_INTERACTIONS Reactome CD8+ T-cells Upregulated - Upregulated Cellular Signaling & Trafficking SIGNALING_BY_GPCR Reactome Classical Monocytes Upregulated Upregulated - GPCR_LIGAND_BINDING Reactome Classical Monocytes Upregulated Upregulated Upregulated GPCR_LIGAND_BINDING Reactome Plasma cells - Upregulated Upregulated CHEMOKINE_RECEPTOR_BIND_CHEMOKINES Reactome Classical Monocytes Upregulated Upregulated Upregulated FORMATION OF BETA-CATENIN TCF COMPLEX Reactome Classical Monocytes Upregulated Upregulated - FORMATION OF BETA-CATENIN TCF COMPLEX Reactome Non-classical Monocytes Upregulated Upregulated Downregulated Cell Cycle & DNA Replication DNA_METHYLATION Reactome Classical Monocytes Upregulated Upregulated - DNA_METHYLATION Reactome Non-classical Monocytes Upregulated Upregulated Downregulated DNA_METHYLATION Reactome Plasma cells Downregulated - Downregulated CELL_CYCLE_MITOTIC Reactome Plasma cells Downregulated - Downregulated CELL_CYCLE_CHECKPOINTS Reactome Plasma cells Downregulated - Downregulated DNA_REPLICATION Reactome Plasma cells Downregulated - Downregulated Metabolism & Biosynthesis RESPIRATORY_ELECTRON_TRANSPORT Reactome Non-classical Monocytes Downregulated Downregulated - HEME_SIGNALING Reactome Immature T-cells Upregulated Upregulated - HEPARAN_SULFATE/HEPARIN METABOLISM Reactome Classical Monocytes Downregulated - Downregulated
利益披露 Disclosure
N. Stabellini, None.. P. B. Parthasarathy, None.. P. A. Rayman, None.. M. Patel, None.. P. G. Pavicic Jr, None.. A. Moen, None.. B. Race, None.. E. Mundell, None.. A. Trevino, None.. J. Powers, None.. J. Ko, None.. B. Moftakhar, None.. T. Mizukami, None.. C. Owusu, None.. A. J. Montero, None.. C. Diaz-Montero, None.

← 返回 AACR 2026 检索